Will there be leadership changes at CVS due to DOJ lawsuit by end of 2025?
CEO resignation • 25%
Board restructuring • 25%
No change • 25%
Other changes • 25%
Official CVS announcements or news reports on leadership changes
DOJ Sues CVS for Unlawful Dispensing of Opioids Since Oct. 17, 2013, Across 9,000 Pharmacies
Dec 19, 2024, 04:20 AM
The U.S. Department of Justice has filed a civil lawsuit against CVS Health Corp., alleging that the company knowingly dispensed controlled substances, including opioids, in violation of the federal Controlled Substances Act. The lawsuit claims that CVS filled prescriptions for dangerous and excessive quantities of opioids, as well as 'trinity' prescriptions, a combination of an opioid, a benzodiazepine, and a muscle relaxant, from October 17, 2013, to the present. The DOJ accuses CVS of ignoring substantial evidence from its own pharmacists and internal data that indicated the dispensing of unlawful prescriptions. The complaint also alleges that CVS sought reimbursement from federal health care programs for these prescriptions, violating the False Claims Act. CVS, which operates over 9,000 pharmacies across the U.S., has stated that it has cooperated with the DOJ's investigation for over four years and strongly disagrees with the allegations, describing them as a 'false narrative.'
View original story
CVS not liable • 25%
CVS found liable • 25%
CVS settles • 25%
Case dismissed • 25%
Increased pharmacist training • 25%
New prescription verification policies • 25%
Other changes • 25%
No significant changes • 25%
Case dismissed • 25%
Walgreens wins • 25%
DOJ wins • 25%
Settlement reached • 25%
CFO change • 25%
Both CEO and CFO change • 25%
No major changes • 25%
CEO change • 25%
Case dismissed • 25%
CVS not found liable • 25%
Settlement reached • 25%
CVS found liable • 25%
$500 million to $1 billion • 25%
Less than $500 million • 25%
No penalty • 25%
Over $1 billion • 25%
CVS • 25%
Walmart • 25%
Other • 25%
Rite Aid • 25%
$1 billion to $5 billion • 25%
Over $5 billion • 25%
No penalty • 25%
Under $1 billion • 25%